Skye Bioscience Faces Investor Class Actions as Firms Court Shareholders Before Jan. 16 Deadline

Plaintiffs base their claims on Skye’s October 6 nimacimab data release that preceded a 60% one-day share decline.

Overview

Investor notices from DJS Law Group, The Gross Law Firm, the Portnoy Law Firm, and Rosen Law Firm urge Skye shareholders to consider lead-plaintiff motions by January 16, 2026.
The proposed class period spans November 4, 2024 through October 3, 2025 for purchasers of Skye securities.
Complaints allege violations of Exchange Act Sections 10(b) and 20(a) and SEC Rule 10b-5 over statements that purportedly overstated nimacimab’s efficacy and prospects.
On October 6, 2025 Skye reported Phase 2a topline results showing the nimacimab monotherapy arm missed the primary weight-loss endpoint and showed lower-than-expected drug exposure.
Skye shares fell about $2.85, roughly 60%, to close at $1.90 on the disclosure date, and while a lawsuit has been filed, no class has been certified.